Allegra patents
This article was originally published in The Tan Sheet
Executive Summary
Five generic companies do not infringe two composition patents for Allegra (fexofenadine), a Newark, N.J. federal court ruled June 29. The ruling granted Barr, Impax, Teva, Mylan and Dr. Reddy's summary judgment of noninfringement on two patents. Barr also received summary judgment of noninfringement on a third composition patent for Allegra, while Barr, Mylan and Impax were denied summary judgment of noninfringement on an Allegra D composition patent. Barr said a total of seven patents remain at issue in its litigation with Aventis and expects the case to go to trial in mid-2005...